Matinas Biopharma (NYSEAMERICAN:MTNB – Get Free Report) issued its earnings results on Friday. The company reported ($0.30) EPS for the quarter, FiscalAI reports.
Matinas Biopharma Price Performance
Shares of NYSEAMERICAN:MTNB traded down $0.01 during trading on Friday, reaching $0.64. 16,345 shares of the company were exchanged, compared to its average volume of 29,557. The firm has a market capitalization of $4.09 million, a PE ratio of -0.32 and a beta of 1.61. The business’s fifty day simple moving average is $0.58 and its 200-day simple moving average is $0.75. Matinas Biopharma has a 12-month low of $0.48 and a 12-month high of $3.09.
Hedge Funds Weigh In On Matinas Biopharma
An institutional investor recently bought a new position in Matinas Biopharma stock. DRW Securities LLC acquired a new stake in shares of Matinas Biopharma Holdings, Inc. (NYSEAMERICAN:MTNB – Free Report) during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm acquired 46,374 shares of the company’s stock, valued at approximately $27,000. DRW Securities LLC owned approximately 0.72% of Matinas Biopharma as of its most recent filing with the Securities & Exchange Commission. 11.77% of the stock is currently owned by hedge funds and other institutional investors.
Matinas Biopharma Company Profile
Matinas Biopharma Inc is a clinical‐stage biopharmaceutical company that specializes in the development of novel lipid‐based drug delivery platforms. Its proprietary Lipid NanoSphere (LNS) technology is designed to encapsulate water‐soluble and hydrophobic therapeutic agents, enabling both oral and intravenous administration. The company’s approach aims to improve drug pharmacokinetics, enhance bioavailability and reduce systemic toxicity compared with conventional formulations.
The lead product candidate, MAT2203, is an oral formulation of amphotericin B being developed for the treatment of cryptococcal meningitis and other life‐threatening fungal infections.
Read More
Receive News & Ratings for Matinas Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Matinas Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
